Orthofix Medical Inc. filed its quarterly report on Form 10-Q with the SEC for the period ended June 30, 2026, disclosing net sales, operating losses, and balance sheet data for the three and six months ended June 30, 2026.

Key Highlights

  • Q2 2026 net sales: $210,933 thousand, compared to $203,121 thousand in Q2 2025, according to the filing.
  • Six-month net sales: $407,641 thousand for the six months ended June 30, 2026, versus $396,767 thousand in the same period of 2025.
  • Q2 2026 operating loss: $(8,134) thousand, an improvement from an operating loss of $(16,003) thousand in Q2 2025.
  • Six-month loss before income taxes: $(35,831) thousand for the six months ended June 30, 2026, per the filing.
  • Total assets: $873,020 thousand as of June 30, 2026, up from $850,647 thousand as of December 31, 2025.
  • Accumulated deficit: $(405,039) thousand as of June 30, 2026, compared to $(368,333) thousand as of December 31, 2025.
  • Shares outstanding: 40,732,608 shares of common stock as of July 31, 2026, per the filing.

Orthofix Medical Q2 2026: Sales Growth Alongside Continued Operating Losses

According to the filing, Orthofix Medical Inc. (Nasdaq Global Select Market: OFIX) reported net sales of $210,933 thousand for the three months ended June 30, 2026, an increase from $203,121 thousand in the comparable prior-year period. For the six months ended June 30, 2026, net sales reached $407,641 thousand, compared to $396,767 thousand for the same period in 2025. The company reported a gross profit of $149,707 thousand for Q2 2026 and $289,253 thousand for the six-month period, versus $139,533 thousand and $261,152 thousand, respectively, in the prior-year periods.

The filing disclosed that operating losses narrowed on a quarterly basis, with an operating loss of $(8,134) thousand in Q2 2026 versus $(16,003) thousand in Q2 2025. For the six months ended June 30, 2026, the operating loss was $(22,570) thousand, compared to $(64,876) thousand in the first half of 2025. Sales, general, and administrative expenses were $138,030 thousand for Q2 2026 and $272,941 thousand for the six-month period. Research and development expenses were $15,944 thousand and $31,264 thousand for the same respective periods.

On the balance sheet, the company reported total assets of $873,020 thousand as of June 30, 2026, up from $850,647 thousand at December 31, 2025. Cash and cash equivalents increased to $103,810 thousand from $82,025 thousand over the same interval. Long-term debt rose to $221,591 thousand from $157,391 thousand. Total shareholders' equity was $429,180 thousand as of June 30, 2026, down from $450,037 thousand at year-end 2025, with the accumulated deficit widening to $(405,039) thousand from $(368,333) thousand. The filing noted that forward-looking statements in the report are subject to the company's cautionary language and the risks described in its 2025 Annual Report on Form 10-K.

What Was Disclosed

Orthofix Medical filed its 10-Q for the quarter ended June 30, 2026, reporting higher net sales and a narrower quarterly operating loss year over year, while total shareholders' equity declined and long-term debt increased relative to December 31, 2025.